Market Overview

Sequenom Shares Edge Higher Following MaterniT21 PLUS LDT News

Related SQNM
UPDATE: Jefferies Resumes Coverage On Sequenom On Revised Revenue/EPS Forecasts
Mid-Day Market Movers For Monday, June 16, 2014

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced today that the MaterniT21™ PLUS laboratory-developed test (LDT) available exclusively through Sequenom Center for Molecular Medicine (Sequenom CMM) will now report as additional findings the presence of certain fetal sex chromosomal aneuploidies, in addition to its identification of autosomal aneuploidies for chromosome 21 (associated with Down syndrome), chromosome 18 (associated with Edwards syndrome), and chromosome 13 (associated with Patau syndrome).  Reporting of these sex aneuploidies will begin for samples received as of Monday, February 4, 2013.

The test will report on the presence of four rare aneuploidies involving an abnormal number of X or Y chromosomes, including female syndromes 45,X (Turner Syndrome) and 47,XXX (Triple X Syndrome), and male syndromes 47,XXY (Klinefelter Syndrome) and 47,XYY.  Results of the blinded clinical validation study set have been submitted for publication in a peer-reviewed journal.

Posted-In: News

 

Most Popular

Related Articles (SQNM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free